Demis Hassabis said that artificial intelligence has the potential to cure all diseases within 10 years [1].
This projection suggests a fundamental shift in global healthcare, moving from reactive treatment to AI-driven eradication of pathology. If realized, such a timeline would accelerate medical breakthroughs by decades and fundamentally alter the pharmaceutical industry.
The claim centers on the ability of AI to model biological systems with unprecedented precision. By analyzing protein folding and genetic sequences, AI tools can identify the root causes of ailments that have long baffled human researchers. This capability allows for the rapid design of targeted therapies that could address a wide range of conditions.
Hassabis said the intersection of machine learning and molecular biology is the primary driver of this progress. The integration of these fields creates a feedback loop where AI predicts a biological outcome and laboratory experiments verify the result. This cycle reduces the time required for drug discovery from years to weeks.
While the timeline is ambitious, it reflects the growing confidence in generative models to solve complex scientific problems. The application of these models to genomics and proteomics provides a map of the human body that was previously invisible. Such a map allows researchers to pinpoint exactly where a disease begins and how to stop it.
However, the transition from laboratory success to widespread clinical application remains a significant hurdle. Regulatory approvals and human clinical trials typically take years to complete. Even with AI-accelerated discovery, the logistical challenges of delivering these cures to a global population persist.
“AI could cure all diseases within 10 years”
This claim underscores the shift toward 'digital biology,' where the primary bottleneck in medicine moves from discovery to delivery. While AI can accelerate the identification of a cure, the actual eradication of all diseases depends on global healthcare infrastructure, political will, and the ability to scale personalized medicine across diverse populations.





